Lessons from patient-derived xenografts for better in vitro modeling of human cancer

Advanced Drug Delivery Reviews

Volumn 79, Issue , 2014, Pages 222-237

  Choi, Stephen Yiu Chuen ^a,c   Lin, Dong ^a,c   Gout, Peter W ^a   Collins, Colin C ^b,c   Xu, Yong ^d   Wang, Yuzhuo ^a,b,c  

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c VANCOUVER PROSTATE CENTRE   (Canada)

^d TIANJIN MEDICAL UNIVERSITY   (China)

Author keywords

Acidic culture conditions; Acidic tumor microenvironment; Cancer associated fibroblasts; Cancer stromal interactions; Extracellular matrix; Patient derived xenografts; Regulatory immune cells; Tumor heterogeneity

Indexed keywords

CELL CULTURE; PHYSIOLOGICAL MODELS; TUMORS;

CULTURE CONDITIONS; EXTRACELLULAR MATRICES; IMMUNE CELLS; PATIENT-DERIVED XENOGRAFTS; TUMOR HETEROGENEITY; TUMOR MICROENVIRONMENT;

DISEASES;

COLLAGEN; CXCL14 CHEMOKINE; DOXORUBICIN; FIBRONECTIN; IMMUNOGLOBULIN; INTERLEUKIN 17; INTERLEUKIN 6; LAMININ; MITOXANTRONE; PROTEOGLYCAN; STAT3 PROTEIN; STROMAL CELL DERIVED FACTOR 1; TOPOTECAN; TRANSFORMING GROWTH FACTOR BETA; ANTINEOPLASTIC AGENT;

APOPTOSIS; BASEMENT MEMBRANE; BIOCOMPATIBILITY; CANCER GRADING; CARCINOGENESIS; CD8+ T LYMPHOCYTE; CELL HETEROGENEITY; CELL POLARITY; COPY NUMBER VARIATION; CYTOSKELETON; DEACETYLATION; DISEASE MODEL; ENERGY METABOLISM; FIBROBLAST; G2 PHASE CELL CYCLE CHECKPOINT; GENE EXPRESSION PROFILING; GENETIC ASSOCIATION; GLYCOLYSIS; HISTOPATHOLOGY; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; IMMUNOREGULATION; IN VITRO STUDY; IN VIVO STUDY; MALIGNANT TRANSFORMATION; MEMBRANE RECONSTITUTION; NATURAL KILLER CELL; NEOPLASM; NONHUMAN; OXIDATIVE PHOSPHORYLATION; OXIDATIVE STRESS; PHENOTYPE; PROTEIN BINDING; PROTEIN CROSS LINKING; PROTEIN DEGRADATION; REGULATORY T LYMPHOCYTE; REVIEW; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; TISSUE ENGINEERING; TUMOR MICROENVIRONMENT; TUMOR XENOGRAFT; ANIMAL; COCULTURE; CULTURE TECHNIQUE; DRUG DESIGN; DRUG SCREENING; NEOPLASMS; PATHOLOGY; PHYSIOLOGY; PROCEDURES;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL CULTURE TECHNIQUES; COCULTURE TECHNIQUES; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; HUMANS; IN VITRO TECHNIQUES; NEOPLASMS; TUMOR MICROENVIRONMENT; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84919659079     PISSN: 0169409X     EISSN: 18728294     Source Type: Journal    
DOI: 10.1016/j.addr.2014.09.009     Document Type: Review

References (323)

1. Ostman A., Augsten M. Cancer-associated fibroblasts and tumor growth-bystanders turning into key players. Curr. Opin. Genet. Dev. 2009, 19:67-73.
2. Siemann D.W. Tumor Microenvironment 2011, Wiley-Blackwell, Chichester, West Sussex, UK, Hoboken, NJ.
3. Bhowmick N.A., Neilson E.G., Moses H.L. Stromal fibroblasts in cancer initiation and progression. Nature 2004, 432:332-337.
4. Sharpless N.E., Depinho R.A. The mighty mouse: genetically engineered mouse models in cancer drug development. Nat. Rev. Drug Discov. 2006, 5:741-754.
5. Voskoglou-Nomikos T., Pater J.L., Seymour L. Clinical predictive value of the in vitro cell line, human xenograft, and mouse allograft preclinical cancer models. Clin. Cancer Res. 2003, 9:4227-4239.
6. Halliwell B. Oxidative stress in cell culture: an under-appreciated problem?. FEBS Lett. 2003, 540:3-6.
7. Briske-Anderson M.J., Finley J.W., Newman S.M. The influence of culture time and passage number on the morphological and physiological development of Caco-2 cells. Proc. Soc. Exp. Biol. Med. 1997, 214:248-257.
8. Wenger S.L., Senft J.R., Sargent L.M., Bamezai R., Bairwa N., Grant S.G. Comparison of established cell lines at different passages by karyotype and comparative genomic hybridization. Biosci. Rep. 2004, 24:631-639.
9. Yu H., Cook T.J., Sinko P.J. Evidence for diminished functional expression of intestinal transporters in Caco-2 cell monolayers at high passages. Pharm. Res. 1997, 14:757-762.
10. Neri A., Nicolson G.L. Phenotypic drift of metastatic and cell-surface properties of mammary adenocarcinoma cell clones during growth in vitro. Int. J. Cancer 1981, 28:731-738.
11. Garber K. From human to mouse and back: 'tumorgraft' models surge in popularity. J. Natl. Cancer Inst. 2009, 101:6-8.
12. Tentler J.J., Tan A.C., Weekes C.D., Jimeno A., Leong S., Pitts T.M., Arcaroli J.J., Messersmith W.A., Eckhardt S.G. Patient-derived tumour xenografts as models for oncology drug development. Nat. Rev. Clin. Oncol. 2012, 9:338-350.
13. Daniel V.C., Marchionni L., Hierman J.S., Rhodes J.T., Devereux W.L., Rudin C.M., Yung R., Parmigiani G., Dorsch M., Peacock C.D., Watkins D.N. A primary xenograft model of small-cell lung cancer reveals irreversible changes in gene expression imposed by culture in vitro. Cancer Res. 2009, 69:3364-3373.
14. DeRose Y.S., Wang G., Lin Y.C., Bernard P.S., Buys S.S., Ebbert M.T., Factor R., Matsen C., Milash B.A., Nelson E., Neumayer L., Randall R.L., Stijleman I.J., Welm B.E., Welm A.L. Tumor grafts derived from women with breast cancer authentically reflect tumor pathology, growth, metastasis and disease outcomes. Nat. Med. 2011, 17:1514-1520.
15. Reyal F., Guyader C., Decraene C., Lucchesi C., Auger N., Assayag F., De Plater L., Gentien D., Poupon M.F., Cottu P., De Cremoux P., Gestraud P., Vincent-Salomon A., Fontaine J.J., Roman-Roman S., Delattre O., Decaudin D., Marangoni E. Molecular profiling of patient-derived breast cancer xenografts. Breast Cancer Res. 2012, 14:R11.
16. McEvoy J., Ulyanov A., Brennan R., Wu G., Pounds S., Zhang J., Dyer M.A. Analysis of MDM2 and MDM4 single nucleotide polymorphisms, mRNA splicing and protein expression in retinoblastoma. PLoS ONE 2012, 7:e42739.
17. Zhang X., Claerhout S., Prat A., Dobrolecki L.E., Petrovic I., Lai Q., Landis M.D., Wiechmann L., Schiff R., Giuliano M., Wong H., Fuqua S.W., Contreras A., Gutierrez C., Huang J., Mao S., Pavlick A.C., Froehlich A.M., Wu M.F., Tsimelzon A., Hilsenbeck S.G., Chen E.S., Zuloaga P., Shaw C.A., Rimawi M.F., Perou C.M., Mills G.B., Chang J.C., Lewis M.T. A renewable tissue resource of phenotypically stable, biologically and ethnically diverse, patient-derived human breast cancer xenograft models. Cancer Res. 2013, 73:4885-4897.
18. Bertotti A., Migliardi G., Galimi F., Sassi F., Torti D., Isella C., Cora D., Di Nicolantonio F., Buscarino M., Petti C., Ribero D., Russolillo N., Muratore A., Massucco P., Pisacane A., Molinaro L., Valtorta E., Sartore-Bianchi A., Risio M., Capussotti L., Gambacorta M., Siena S., Medico E., Sapino A., Marsoni S., Comoglio P.M., Bardelli A., Trusolino L. A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer. Cancer Discov. 2011, 1:508-523.
19. Fichtner I., Rolff J., Soong R., Hoffmann J., Hammer S., Sommer A., Becker M., Merk J. Establishment of patient-derived non-small cell lung cancer xenografts as models for the identification of predictive biomarkers. Clin. Cancer Res. 2008, 14:6456-6468.
20. Lin D., Wyatt A.W., Xue H., Wang Y., Dong X., Haegert A., Wu R., Brahmbhatt S., Mo F., Jong L., Bell R.H., Anderson S., Hurtado-Coll A., Fazli L., Sharma M., Beltran H., Rubin M., Cox M., Gout P.W., Morris J., Goldenberg L., Volik S.V., Gleave M.E., Collins C.C. High fidelity patient-derived xenografts for accelerating prostate cancer discovery and drug development. Cancer Res. 2014, 74:1272-1283.
21. Eigeliene N., Härkönen P., Erkkola R. Effects of estradiol and medroxyprogesterone acetate on morphology, proliferation and apoptosis of human breast tissue in organ cultures. BMC Cancer 2006, 6:246.
22. Gu L., Liao Z., Hoang D.T., Dagvadorj A., Gupta S., Blackmon S., Ellsworth E., Talati P., Leiby B., Zinda M., Lallas C.D., Trabulsi E.J., McCue P., Gomella L., Huszar D., Nevalainen M.T. Pharmacologic inhibition of Jak2-Stat5 signaling By Jak2 inhibitor AZD1480 potently suppresses growth of both primary and castrate-resistant prostate cancer. Clin. Cancer Res. 2013, 19:5658-5674.
23. Baguley B.C., Marshall E.S., Finlay G.J. Short-term cultures of clinical tumor material: potential contributions to oncology research. Oncol. Res. 1999, 11:115-124.
24. Donnell R.L.O., McCormick A., Mukhopadhyay A., Woodhouse L.C., Moat M., Grundy A., Dixon M., Kaufman A., Soohoo S., Elattar A., Curtin N.J., Edmondson R.J. The use of ovarian cancer cells from patients undergoing surgery to generate primary cultures capable of undergoing functional analysis. PLoS ONE 2014, 9:e90604.
25. Furneaux C.E., Marshall E.S., Yeoh K., Monteith S.J., Mews P.J., Sansur C.A., Oskouian R.J., Sharples K.J., Baguley B.C. Cell cycle times of short-term cultures of brain cancers as predictors of survival. Br. J. Cancer 2008, 99:1678-1683.
26. Thibaudeau L., Quent V.M., Holzapfel B.M., Taubenberger A.V., Straub M., Hutmacher D.W. Mimicking breast cancer-induced bone metastasis in vivo: current transplantation models and advanced humanized strategies. Cancer Metastasis Rev. 2014, 33:721-735.
27. Kostenuik P.J., Nguyen H.Q., McCabe J., Warmington K.S., Kurahara C., Sun N., Chen C., Li L., Cattley R.C., Van G., Scully S., Elliott R., Grisanti M., Morony S., Tan H.L., Asuncion F., Li X., Ominsky M.S., Stolina M., Dwyer D., Dougall W.C., Hawkins N., Boyle W.J., Simonet W.S., Sullivan J.K. Denosumab, a fully human monoclonal antibody to RANKL, inhibits bone resorption and increases BMD in knock-in mice that express chimeric (murine/human) RANKL. J. Bone Miner. Res. 2009, 24:182-195.
28. Vudattu N.K., Waldron-Lynch F., Truman L.A., Deng S., Preston-Hurlburt P., Torres R., Raycroft M.T., Mamula M.J., Herold K.C. Humanized mice as a model for aberrant responses in human T cell immunotherapy. J. Immunol. 2014, 193:587-596.
29. Proia D.A., Kuperwasser C. Reconstruction of human mammary tissues in a mouse model. Nat. Protoc. 2006, 1:206-214.
30. Thibaudeau L., Taubenberger A.V., Holzapfel B.M., Quent V.M., Fuehrmann T., Hesami P., Brown T.D., Dalton P.D., Power C.A., Hollier B.G., Hutmacher D.W. A tissue-engineered humanized xenograft model of human breast cancer metastasis to bone. Dis. Model. Mech. 2014, 7:299-309.
31. Wu M., Jung L., Cooper A.B., Fleet C., Chen L., Breault L., Clark K., Cai Z., Vincent S., Bottega S., Shen Q., Richardson A., Bosenburg M., Naber S.P., DePinho R.A., Kuperwasser C., Robinson M.O. Dissecting genetic requirements of human breast tumorigenesis in a tissue transgenic model of human breast cancer in mice. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:7022-7027.
32. Melkus M.W., Estes J.D., Padgett-Thomas A., Gatlin J., Denton P.W., Othieno F.A., Wege A.K., Haase A.T., Garcia J.V. Humanized mice mount specific adaptive and innate immune responses to EBV and TSST-1. Nat. Med. 2006, 12:1316-1322.
33. Wang J., Xia T.S., Liu X.A., Ding Q., Du Q., Yin H., Wang S. A novel orthotopic and metastatic mouse model of breast cancer in human mammary microenvironment. Breast Cancer Res. Treat. 2010, 120:337-344.
34. Hesami P., Holzapfel B.M., Taubenberger A., Roudier M., Fazli L., Sieh S., Thibaudeau L., Gregory L.S., Hutmacher D.W., Clements J.A. A humanized tissue-engineered in vivo model to dissect interactions between human prostate cancer cells and human bone. Clin. Exp. Metastasis 2014, 31(4):435-446.
35. Holzapfel B.M., Wagner F., Loessner D., Holzapfel N.P., Thibaudeau L., Crawford R., Ling M.T., Clements J.A., Russell P.J., Hutmacher D.W. Species-specific homing mechanisms of human prostate cancer metastasis in tissue engineered bone. Biomaterials 2014, 35:4108-4115.
36. Wahl A., Victor Garcia J. The use of BLT humanized mice to investigate the immune reconstitution of the gastrointestinal tract. J. Immunol. Methods 2014, 410:28-33.
37. Cohen J. Toxicology. 'Humanized' mouse detects deadly drug side effects. Science 2014, 344:244-245.
38. Bissell M.J., Hines W.C. Why don't we get more cancer? A proposed role of the microenvironment in restraining cancer progression. Nat. Med. 2011, 17:320-329.
39. Bhowmick N.A., Chytil A., Plieth D., Gorska A.E., Dumont N., Shappell S., Washington M.K., Neilson E.G., Moses H.L. TGF-beta signaling in fibroblasts modulates the oncogenic potential of adjacent epithelia. Science 2004, 303:848-851.
40. Kaplan R.N., Rafii S., Lyden D. Preparing the "soil": the premetastatic niche. Cancer Res. 2006, 66:11089-11093.
41. Martin-Belmonte F., Perez-Moreno M. Epithelial cell polarity, stem cells and cancer. Nat. Rev. Cancer 2012, 12:23-38.
42. Sundararaghavan H.G., Saunders R.L., Hammer D.A., Burdick J.A. Fiber alignment directs cell motility over chemotactic gradients. Biotechnol. Bioeng. 2013, 110:1249-1254.
43. Schedin P., Keely P.J. Mammary gland ECM remodeling, stiffness, and mechanosignaling in normal development and tumor progression. Cold Spring Harb. Perspect. Biol. 2011, 3:a003228.
44. Infanger D.W., Lynch M.E., Fischbach C. Engineered culture models for studies of tumor-microenvironment interactions. Annu. Rev. Biomed. Eng. 2013, 15:29-53.
45. Vaupel P. Hypoxia and aggressive tumor phenotype: implications for therapy and prognosis. Oncologist 2008, 13(Suppl. 3):21-26.
46. Chung A.S., Lee J., Ferrara N. Targeting the tumour vasculature: insights from physiological angiogenesis. Nat. Rev. Cancer 2010, 10:505-514.
47. Wilson W.R., Hay M.P. Targeting hypoxia in cancer therapy. Nat. Rev. Cancer 2011, 11:393-410.
48. Vaupel P., Mayer A., Höckel M. Tumor hypoxia and malignant progression. Methods Enzymol. 2004, 381:335-354.
49. Vaupel P., Mayer A. Hypoxia in cancer: significance and impact on clinical outcome. Cancer Metastasis Rev. 2007, 26:225-239.
50. Cramer T., Johnson R.S. A novel role for the hypoxia inducible transcription factor HIF-1alpha: critical regulation of inflammatory cell function. Cell Cycle 2003, 2:192-193.
51. Azmi A.S., Bao B., Sarkar F.H. Exosomes in cancer development, metastasis, and drug resistance: a comprehensive review. Cancer Metastasis Rev. 2013, 32:623-642.
52. Robbins P.D., Morelli A.E. Regulation of immune responses by extracellular vesicles. Nat. Rev. Immunol. 2014, 14:195-208.
53. Guo W., Giancotti F.G. Integrin signalling during tumour progression. Nat. Rev. Mol. Cell Biol. 2004, 5:816-826.
54. Lu P., Takai K., Weaver V.M., Werb Z. Extracellular matrix degradation and remodeling in development and disease. Cold Spring Harb. Perspect. Biol. 2011, 3.
55. Desgrosellier J.S., Cheresh D.A. Integrins in cancer: biological implications and therapeutic opportunities. Nat. Rev. Cancer 2010, 10:9-22.
56. Hynes R.O. Integrins: versatility, modulation, and signaling in cell adhesion. Cell 1992, 69:11-25.
57. Lelièvre S.A. Contributions of extracellular matrix signaling and tissue architecture to nuclear mechanisms and spatial organization of gene expression control. Biochim. Biophys. Acta 2009, 1790:925-935.
58. Jinka R., Kapoor R., Sistla P.G., Raj T.A., Pande G. Alterations in cell-extracellular matrix interactions during progression of cancers. Int. J. Cell Biol. 2012, 2012:219196.
59. Nelson C.M., Bissell M.J. Modeling dynamic reciprocity: engineering three-dimensional culture models of breast architecture, function, and neoplastic transformation. Semin. Cancer Biol. 2005, 15:342-352.
60. Kumar S., Weaver V.M. Mechanics, malignancy, and metastasis: the force journey of a tumor cell. Cancer Metastasis Rev. 2009, 28:113-127.
61. Weaver V.M., Petersen O.W., Wang F., Larabell C.A., Briand P., Damsky C., Bissell M.J. Reversion of the malignant phenotype of human breast cells in three-dimensional culture and in vivo by integrin blocking antibodies. J. Cell Biol. 1997, 137:231-245.
62. Weaver V.M., Lelièvre S., Lakins J.N., Chrenek M.A., Jones J.C., Giancotti F., Werb Z., Bissell M.J. beta4 integrin-dependent formation of polarized three-dimensional architecture confers resistance to apoptosis in normal and malignant mammary epithelium. Cancer Cell 2002, 2:205-216.
63. Rizki A., Weaver V.M., Lee S.Y., Rozenberg G.I., Chin K., Myers C.A., Bascom J.L., Mott J.D., Semeiks J.R., Grate L.R., Mian I.S., Borowsky A.D., Jensen R.A., Idowu M.O., Chen F., Chen D.J., Petersen O.W., Gray J.W., Bissell M.J. A human breast cell model of preinvasive to invasive transition. Cancer Res. 2008, 68:1378-1387.
64. Fraley S.I., Feng Y., Krishnamurthy R., Kim D.H., Celedon A., Longmore G.D., Wirtz D. A distinctive role for focal adhesion proteins in three-dimensional cell motility. Nat. Cell Biol. 2010, 12:598-604.
65. Fischbach C., Kong H.J., Hsiong S.X., Evangelista M.B., Yuen W., Mooney D.J. Cancer cell angiogenic capability is regulated by 3D culture and integrin engagement. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:399-404.
66. Pickl M., Ries C.H. Comparison of 3D and 2D tumor models reveals enhanced HER2 activation in 3D associated with an increased response to trastuzumab. Oncogene 2009, 28:461-468.
67. Jain R.K., Duda D.G., Clark J.W., Loeffler J.S. Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nat. Clin. Pract. Oncol. 2006, 3:24-40.
68. Ingber D.E. Cancer as a disease of epithelial-mesenchymal interactions and extracellular matrix regulation. Differentiation 2002, 70:547-560.
69. Levental K.R., Yu H., Kass L., Lakins J.N., Egeblad M., Erler J.T., Fong S.F., Csiszar K., Giaccia A., Weninger W., Yamauchi M., Gasser D.L., Weaver V.M. Matrix crosslinking forces tumor progression by enhancing integrin signaling. Cell 2009, 139:891-906.
70. Zhu G.G., Risteli L., Mäkinen M., Risteli J., Kauppila A., Stenbäck F. Immunohistochemical study of type I collagen and type I pN-collagen in benign and malignant ovarian neoplasms. Cancer 1995, 75:1010-1017.
71. Kauppila S., Stenbäck F., Risteli J., Jukkola A., Risteli L. Aberrant type I and type III collagen gene expression in human breast cancer in vivo. J. Pathol. 1998, 186:262-268.
72. Nasser N.J. Heparanase involvement in physiology and disease. Cell. Mol. Life Sci. 2008, 65:1706-1715.
73. Dvorak H.F. Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N. Engl. J. Med. 1986, 315:1650-1659.
74. Matsumura Y. Cancer stromal targeting (CAST) therapy. Adv. Drug Deliv. Rev. 2012, 64:710-719.
75. Provenzano P.P., Eliceiri K.W., Campbell J.M., Inman D.R., White J.G., Keely P.J. Collagen reorganization at the tumor-stromal interface facilitates local invasion. BMC Med. 2006, 4:38.
76. Ilan N., Elkin M., Vlodavsky I. Regulation, function and clinical significance of heparanase in cancer metastasis and angiogenesis. Int. J. Biochem. Cell Biol. 2006, 38:2018-2039.
77. Kessenbrock K., Plaks V., Werb Z. Matrix metalloproteinases: regulators of the tumor microenvironment. Cell 2010, 141:52-67.
78. Lu P., Weaver V.M., Werb Z. The extracellular matrix: a dynamic niche in cancer progression. J. Cell Biol. 2012, 196:395-406.
79. Hughes C.S., Postovit L.M., Lajoie G.A. Matrigel: a complex protein mixture required for optimal growth of cell culture. Proteomics 2010, 10:1886-1890.
80. Rowe R.G., Weiss S.J. Breaching the basement membrane: who, when and how?. Trends Cell Biol. 2008, 18:560-574.
81. Haga H., Irahara C., Kobayashi R., Nakagaki T., Kawabata K. Collective movement of epithelial cells on a collagen gel substrate. Biophys. J. 2005, 88:2250-2256.
82. Zeugolis D.I., Paul R.G., Attenburrow G. Factors influencing the properties of reconstituted collagen fibers prior to self-assembly: animal species and collagen extraction method. J. Biomed. Mater. Res. A 2008, 86:892-904.
83. Kutys M.L., Doyle A.D., Yamada K.M. Regulation of cell adhesion and migration by cell-derived matrices. Exp. Cell Res. 2013, 319:2434-2439.
84. Quiros R.M., Valianou M., Kwon Y., Brown K.M., Godwin A.K., Cukierman E. Ovarian normal and tumor-associated fibroblasts retain in vivo stromal characteristics in a 3-D matrix-dependent manner. Gynecol. Oncol. 2008, 110:99-109.
85. Amatangelo M.D., Bassi D.E., Klein-Szanto A.J., Cukierman E. Stroma-derived three-dimensional matrices are necessary and sufficient to promote desmoplastic differentiation of normal fibroblasts. Am. J. Pathol. 2005, 167:475-488.
86. Castelló-Cros R., Khan D.R., Simons J., Valianou M., Cukierman E. Staged stromal extracellular 3D matrices differentially regulate breast cancer cell responses through PI3K and beta1-integrins. BMC Cancer 2009, 9:94.
87. Kenny P.A., Lee G.Y., Myers C.A., Neve R.M., Semeiks J.R., Spellman P.T., Lorenz K., Lee E.H., Barcellos-Hoff M.H., Petersen O.W., Gray J.W., Bissell M.J. The morphologies of breast cancer cell lines in three-dimensional assays correlate with their profiles of gene expression. Mol. Oncol. 2007, 1:84-96.
88. Wang F., Weaver V.M., Petersen O.W., Larabell C.A., Dedhar S., Briand P., Lupu R., Bissell M.J. Reciprocal interactions between beta1-integrin and epidermal growth factor receptor in three-dimensional basement membrane breast cultures: a different perspective in epithelial biology. Proc. Natl. Acad. Sci. U. S. A. 1998, 95:14821-14826.
89. Hosseinkhani H., Hosseinkhani M., Tian F., Kobayashi H., Tabata Y. Osteogenic differentiation of mesenchymal stem cells in self-assembled peptide-amphiphile nanofibers. Biomaterials 2006, 27:4079-4086.
90. Rhodes N.P., Srivastava J.K., Smith R.F., Longinotti C. Metabolic and histological analysis of mesenchymal stem cells grown in 3-D hyaluronan-based scaffolds. J. Mater. Sci. Mater. Med. 2004, 15:391-395.
91. Hutmacher D.W., Horch R.E., Loessner D., Rizzi S., Sieh S., Reichert J.C., Clements J.A., Beier J.P., Arkudas A., Bleiziffer O., Kneser U. Translating tissue engineering technology platforms into cancer research. J. Cell. Mol. Med. 2009, 13:1417-1427.
92. Yamada K.M., Cukierman E. Modeling tissue morphogenesis and cancer in 3D. Cell 2007, 130:601-610.
93. Griffith L.G., Swartz M.A. Capturing complex 3D tissue physiology in vitro. Nat. Rev. Mol. Cell Biol. 2006, 7:211-224.
94. Debnath J., Brugge J.S. Modelling glandular epithelial cancers in three-dimensional cultures. Nat. Rev. Cancer 2005, 5:675-688.
95. Pathak A., Kumar S. Independent regulation of tumor cell migration by matrix stiffness and confinement. Proc. Natl. Acad. Sci. U. S. A. 2012, 109:10334-10339.
96. Ulrich T.A., Jain A., Tanner K., MacKay J.L., Kumar S. Probing cellular mechanobiology in three-dimensional culture with collagen-agarose matrices. Biomaterials 2010, 31:1875-1884.
97. Nyga A., Cheema U., Loizidou M. 3D tumour models: novel in vitro approaches to cancer studies. J. Cell Commun. Signal. 2011, 5:239-248.
98. Kimlin L.C., Casagrande G., Virador V.M. In vitro three-dimensional (3D) models in cancer research: an update. Mol. Carcinog. 2013, 52:167-182.
99. Fuller E.S., Howell V.M. Culture models to define key mediators of cancer matrix remodeling. Front. Oncol. 2014, 4:57.
100. Mintz B., Illmensee K. Normal genetically mosaic mice produced from malignant teratocarcinoma cells. Proc. Natl. Acad. Sci. U. S. A. 1975, 72:3585-3589.
101. Sonnenschein C., Soto A.M., Rangarajan A., Kulkarni P. Competing views on cancer. J. Biosci. 2014, 39:281-302.
102. Sonnenschein C., Soto A.M. Theories of carcinogenesis: an emerging perspective. Semin. Cancer Biol. 2008, 18:372-377.
103. Soto A.M., Sonnenschein C. Environmental causes of cancer: endocrine disruptors as carcinogens. Nat. Rev. Endocrinol. 2010, 6:363-370.
104. Martinez-Outschoorn U.E., Trimmer C., Lin Z., Whitaker-Menezes D., Chiavarina B., Zhou J., Wang C., Pavlides S., Martinez-Cantarin M.P., Capozza F., Witkiewicz A.K., Flomenberg N., Howell A., Pestell R.G., Caro J., Lisanti M.P., Sotgia F. Autophagy in cancer associated fibroblasts promotes tumor cell survival: role of hypoxia, HIF1 induction and NFκB activation in the tumor stromal microenvironment. Cell Cycle 2010, 9:3515-3533.
105. Olumi A.F., Grossfeld G.D., Hayward S.W., Carroll P.R., Tlsty T.D., Cunha G.R. Carcinoma-associated fibroblasts direct tumor progression of initiated human prostatic epithelium. Cancer Res. 1999, 59:5002-5011.
106. Orimo A., Gupta P.B., Sgroi D.C., Arenzana-Seisdedos F., Delaunay T., Naeem R., Carey V.J., Richardson A.L., Weinberg R.A. Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell 2005, 121:335-348.
107. Yang G., Rosen D.G., Zhang Z., Bast R.C., Mills G.B., Colacino J.A., Mercado-Uribe I., Liu J. The chemokine growth-regulated oncogene 1 (Gro-1) links RAS signaling to the senescence of stromal fibroblasts and ovarian tumorigenesis. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:16472-16477.
108. Hwang R.F., Moore T., Arumugam T., Ramachandran V., Amos K.D., Rivera A., Ji B., Evans D.B., Logsdon C.D. Cancer-associated stromal fibroblasts promote pancreatic tumor progression. Cancer Res. 2008, 68:918-926.
109. Hu M., Peluffo G., Chen H., Gelman R., Schnitt S., Polyak K. Role of COX-2 in epithelial-stromal cell interactions and progression of ductal carcinoma in situ of the breast. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:3372-3377.
110. Erez N., Truitt M., Olson P., Arron S.T., Hanahan D. Cancer-associated fibroblasts are activated in incipient neoplasia to orchestrate tumor-promoting inflammation in an NF-kappaB-dependent manner. Cancer Cell 2010, 17:135-147.
111. Vicent S., Sayles L.C., Vaka D., Khatri P., Gevaert O., Chen R., Zheng Y., Gillespie A.K., Clarke N., Xu Y., Shrager J., Hoang C.D., Plevritis S., Butte A.J., Sweet-Cordero E.A. Cross-species functional analysis of cancer-associated fibroblasts identifies a critical role for CLCF1 and IL-6 in non-small cell lung cancer in vivo. Cancer Res. 2012, 72:5744-5756.
112. Kalluri R., Zeisberg M. Fibroblasts in cancer. Nat. Rev. Cancer 2006, 6:392-401.
113. Giannoni E., Bianchini F., Masieri L., Serni S., Torre E., Calorini L., Chiarugi P. Reciprocal activation of prostate cancer cells and cancer-associated fibroblasts stimulates epithelial-mesenchymal transition and cancer stemness. Cancer Res. 2010, 70:6945-6956.
114. Hanahan D., Coussens L.M. Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell 2012, 21:309-322.
115. Crawford Y., Kasman I., Yu L., Zhong C., Wu X., Modrusan Z., Kaminker J., Ferrara N. PDGF-C mediates the angiogenic and tumorigenic properties of fibroblasts associated with tumors refractory to anti-VEGF treatment. Cancer Cell 2009, 15:21-34.
116. Olive K.P., Jacobetz M.A., Davidson C.J., Gopinathan A., McIntyre D., Honess D., Madhu B., Goldgraben M.A., Caldwell M.E., Allard D., Frese K.K., Denicola G., Feig C., Combs C., Winter S.P., Ireland-Zecchini H., Reichelt S., Howat W.J., Chang A., Dhara M., Wang L., Rückert F., Grützmann R., Pilarsky C., Izeradjene K., Hingorani S.R., Huang P., Davies S.E., Plunkett W., Egorin M., Hruban R.H., Whitebread N., McGovern K., Adams J., Iacobuzio-Donahue C., Griffiths J., Tuveson D.A. Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science 2009, 324:1457-1461.
117. Straussman R., Morikawa T., Shee K., Barzily-Rokni M., Qian Z.R., Du J., Davis A., Mongare M.M., Gould J., Frederick D.T., Cooper Z.A., Chapman P.B., Solit D.B., Ribas A., Lo R.S., Flaherty K.T., Ogino S., Wargo J.A., Golub T.R. Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature 2012, 487:500-504.
118. Sun Y., Campisi J., Higano C., Beer T.M., Porter P., Coleman I., True L., Nelson P.S. Treatment-induced damage to the tumor microenvironment promotes prostate cancer therapy resistance through WNT16B. Nat. Med. 2012, 18:1359-1368.
119. Hayward S.W., Wang Y., Cao M., Hom Y.K., Zhang B., Grossfeld G.D., Sudilovsky D., Cunha G.R. Malignant transformation in a nontumorigenic human prostatic epithelial cell line. Cancer Res. 2001, 61:8135-8142.
120. Vindrieux D., Escobar P., Lazennec G. Emerging roles of chemokines in prostate cancer. Endocr. Relat. Cancer 2009, 16:663-673.
121. Lu T., Burdelya L.G., Swiatkowski S.M., Boiko A.D., Howe P.H., Stark G.R., Gudkov A.V. Secreted transforming growth factor beta2 activates NF-kappaB, blocks apoptosis, and is essential for the survival of some tumor cells. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:7112-7117.
122. Li X., Placencio V., Iturregui J.M., Uwamariya C., Sharif-Afshar A.R., Koyama T., Hayward S.W., Bhowmick N.A. Prostate tumor progression is mediated by a paracrine TGF-beta/Wnt3a signaling axis. Oncogene 2008, 27:7118-7130.
123. Ao M., Franco O.E., Park D., Raman D., Williams K., Hayward S.W. Cross-talk between paracrine-acting cytokine and chemokine pathways promotes malignancy in benign human prostatic epithelium. Cancer Res. 2007, 67:4244-4253.
124. Cheng N., Bhowmick N.A., Chytil A., Gorksa A.E., Brown K.A., Muraoka R., Arteaga C.L., Neilson E.G., Hayward S.W., Moses H.L. Loss of TGF-beta type II receptor in fibroblasts promotes mammary carcinoma growth and invasion through upregulation of TGF-alpha-, MSP- and HGF-mediated signaling networks. Oncogene 2005, 24:5053-5068.
125. Cheng N., Chytil A., Shyr Y., Joly A., Moses H.L. Enhanced hepatocyte growth factor signaling by type II transforming growth factor-beta receptor knockout fibroblasts promotes mammary tumorigenesis. Cancer Res. 2007, 67:4869-4877.
126. Müller A., Homey B., Soto H., Ge N., Catron D., Buchanan M.E., McClanahan T., Murphy E., Yuan W., Wagner S.N., Barrera J.L., Mohar A., Verástegui E., Zlotnik A. Involvement of chemokine receptors in breast cancer metastasis. Nature 2001, 410:50-56.
127. Gaggioli C., Hooper S., Hidalgo-Carcedo C., Grosse R., Marshall J.F., Harrington K., Sahai E. Fibroblast-led collective invasion of carcinoma cells with differing roles for RhoGTPases in leading and following cells. Nat. Cell Biol. 2007, 9:1392-1400.
128. Clark A.K., Taubenberger A.V., Taylor R.A., Niranjan B., Chea Z.Y., Zotenko E., Sieh S., Pedersen J.S., Norden S., Frydenberg M., Grummet J.P., Pook D.W., Stirzaker C., Clark S.J., Lawrence M.G., Ellem S.J., Hutmacher D.W., Risbridger G.P., BioResource A.P.C. A bioengineered microenvironment to quantitatively measure the tumorigenic properties of cancer-associated fibroblasts in human prostate cancer. Biomaterials 2013, 34:4777-4785.
129. Horie M., Saito A., Mikami Y., Ohshima M., Morishita Y., Nakajima J., Kohyama T., Nagase T. Characterization of human lung cancer-associated fibroblasts in three-dimensional in vitro co-culture model. Biochem. Biophys. Res. Commun. 2012, 423:158-163.
130. Kiskowski M.A., Jackson R.S., Banerjee J., Li X., Kang M., Iturregui J.M., Franco O.E., Hayward S.W., Bhowmick N.A. Role for stromal heterogeneity in prostate tumorigenesis. Cancer Res. 2011, 71:3459-3470.
131. Trimboli A.J., Cantemir-Stone C.Z., Li F., Wallace J.A., Merchant A., Creasap N., Thompson J.C., Caserta E., Wang H., Chong J.L., Naidu S., Wei G., Sharma S.M., Stephens J.A., Fernandez S.A., Gurcan M.N., Weinstein M.B., Barsky S.H., Yee L., Rosol T.J., Stromberg P.C., Robinson M.L., Pepin F., Hallett M., Park M., Ostrowski M.C., Leone G. Pten in stromal fibroblasts suppresses mammary epithelial tumours. Nature 2009, 461:1084-1091.
132. O'Connell J.T., Sugimoto H., Cooke V.G., MacDonald B.A., Mehta A.I., LeBleu V.S., Dewar R., Rocha R.M., Brentani R.R., Resnick M.B., Neilson E.G., Zeisberg M., Kalluri R. VEGF-A and tenascin-C produced by S100A4+ stromal cells are important for metastatic colonization. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:16002-16007.
133. Herrera M., Islam A.B., Herrera A., Martín P., García V., Silva J., Garcia J.M., Salas C., Casal I., de Herreros A.G., Bonilla F., Peña C. Functional heterogeneity of cancer-associated fibroblasts from human colon tumors shows specific prognostic gene expression signature. Clin. Cancer Res. 2013, 19:5914-5926.
134. Lesterhuis W.J., Punt C.J., Hato S.V., Eleveld-Trancikova D., Jansen B.J., Nierkens S., Schreibelt G., de Boer A., Van Herpen C.M., Kaanders J.H., van Krieken J.H., Adema G.J., Figdor C.G., de Vries I.J. Platinum-based drugs disrupt STAT6-mediated suppression of immune responses against cancer in humans and mice. J. Clin. Invest. 2011, 121:3100-3108.
135. Ramakrishnan R., Assudani D., Nagaraj S., Hunter T., Cho H.I., Antonia S., Altiok S., Celis E., Gabrilovich D.I. Chemotherapy enhances tumor cell susceptibility to CTL-mediated killing during cancer immunotherapy in mice. J. Clin. Invest. 2010, 120:1111-1124.
136. Tewari N., Zaitoun A.M., Arora A., Madhusudan S., Ilyas M., Lobo D.N. The presence of tumour-associated lymphocytes confers a good prognosis in pancreatic ductal adenocarcinoma: an immunohistochemical study of tissue microarrays. BMC Cancer 2013, 13:436.
137. Rusakiewicz S., Semeraro M., Sarabi M., Desbois M., Locher C., Mendez R., Vimond N., Concha A., Garrido F., Isambert N., Chaigneau L., Le Brun-Ly V., Dubreuil P., Cremer I., Caignard A., Poirier-Colame V., Chaba K., Flament C., Halama N., Jäger D., Eggermont A., Bonvalot S., Commo F., Terrier P., Opolon P., Emile J.F., Coindre J.M., Kroemer G., Chaput N., Le Cesne A., Blay J.Y., Zitvogel L. Immune infiltrates are prognostic factors in localized gastrointestinal stromal tumors. Cancer Res. 2013, 73:3499-3510.
138. Mhawech-Fauceglia P., Wang D., Ali L., Lele S., Huba M.A., Liu S., Odunsi K. Intraepithelial T cells and tumor-associated macrophages in ovarian cancer patients. Cancer Immun. 2013, 13:1.
139. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.
140. Heemskerk B., Kvistborg P., Schumacher T.N. The cancer antigenome. EMBO J. 2013, 32:194-203.
141. Garg A.D., Dudek A.M., Agostinis P. Cancer immunogenicity, danger signals, and DAMPs: what, when, and how?. Biofactors 2013, 39:355-367.
142. Tesniere A., Panaretakis T., Kepp O., Apetoh L., Ghiringhelli F., Zitvogel L., Kroemer G. Molecular characteristics of immunogenic cancer cell death. Cell Death Differ. 2008, 15:3-12.
143. Dunn G.P., Old L.J., Schreiber R.D. The immunobiology of cancer immunosurveillance and immunoediting. Immunity 2004, 21:137-148.
144. Choi S.Y., Gout P.W., Collins C.C., Wang Y. Epithelial immune cell-like transition (EIT): a proposed transdifferentiation process underlying immune-suppressive activity of epithelial cancers. Differentiation 2012, 83:293-298.
145. Jackson C., Ruzevick J., Phallen J., Belcaid Z., Lim M. Challenges in immunotherapy presented by the glioblastoma multiforme microenvironment. Clin. Dev. Immunol. 2011, 2011:732413.
146. Kershaw M.H., Westwood J.A., Darcy P.K. Gene-engineered T cells for cancer therapy. Nat. Rev. Cancer 2013, 13:525-541.
147. Jing W., Orentas R.J., Johnson B.D. Induction of immunity to neuroblastoma early after syngeneic hematopoietic stem cell transplantation using a novel mouse tumor vaccine. Biol. Blood Marrow Transplant. 2007, 13:277-292.
148. Mundhada S., Shaw J., Mori S., Savary C.A., Mullen C.A. Cellular tumor vaccines administered after T cell-depleted allogeneic bone marrow transplantation induce effective anti-tumor immune responses. Leuk. Lymphoma 2005, 46:571-580.
149. Diab A., Jenq R.R., Rizzuto G.A., Cohen A.D., Huggins D.W., Merghoub T., Engelhorn M.E., Guevara-Patiño J.A., Suh D., Hubbard-Lucey V.M., Kochman A.A., Chen S., Zhong H., Wolchok J.D., van den Brink M.R., Houghton A.N., Perales M.A. Enhanced responses to tumor immunization following total body irradiation are time-dependent. PLoS ONE 2013, 8:e82496.
150. Chinnasamy D., Tran E., Yu Z., Morgan R.A., Restifo N.P., Rosenberg S.A. Simultaneous targeting of tumor antigens and the tumor vasculature using T lymphocyte transfer synergize to induce regression of established tumors in mice. Cancer Res. 2013, 73:3371-3380.
151. Gattinoni L., Finkelstein S.E., Klebanoff C.A., Antony P.A., Palmer D.C., Spiess P.J., Hwang L.N., Yu Z., Wrzesinski C., Heimann D.M., Surh C.D., Rosenberg S.A., Restifo N.P. Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells. J. Exp. Med. 2005, 202:907-912.
152. Yu Y., Cho H.I., Wang D., Kaosaard K., Anasetti C., Celis E., Yu X.Z. Adoptive transfer of Tc1 or Tc17 cells elicits antitumor immunity against established melanoma through distinct mechanisms. J. Immunol. 2013, 190:1873-1881.
153. Wrzesinski C., Paulos C.M., Gattinoni L., Palmer D.C., Kaiser A., Yu Z., Rosenberg S.A., Restifo N.P. Hematopoietic stem cells promote the expansion and function of adoptively transferred antitumor CD8 T cells. J. Clin. Invest. 2007, 117:492-501.
154. Bracci L., Moschella F., Sestili P., La Sorsa V., Valentini M., Canini I., Baccarini S., Maccari S., Ramoni C., Belardelli F., Proietti E. Cyclophosphamide enhances the antitumor efficacy of adoptively transferred immune cells through the induction of cytokine expression, B-cell and T-cell homeostatic proliferation, and specific tumor infiltration. Clin. Cancer Res. 2007, 13:644-653.
155. Sakaguchi S. Naturally arising CD4+ regulatory T cells for immunologic self-tolerance and negative control of immune responses. Annu. Rev. Immunol. 2004, 22:531-562.
156. Sakaguchi S., Yamaguchi T., Nomura T., Ono M. Regulatory T cells and immune tolerance. Cell 2008, 133:775-787.
157. Wilke C.M., Wu K., Zhao E., Wang G., Zou W. Prognostic significance of regulatory T cells in tumor. Int. J. Cancer 2010, 127:748-758.
158. Curiel T.J., Coukos G., Zou L., Alvarez X., Cheng P., Mottram P., Evdemon-Hogan M., Conejo-Garcia J.R., Zhang L., Burow M., Zhu Y., Wei S., Kryczek I., Daniel B., Gordon A., Myers L., Lackner A., Disis M.L., Knutson K.L., Chen L., Zou W. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat. Med. 2004, 10:942-949.
159. Zhou S., Xu S., Tao H., Zhen Z., Chen G., Zhang Z., Yang Y. CCR7 expression and intratumoral FOXP3(+) regulatory T cells are correlated with overall survival and lymph node metastasis in gastric cancer. PLoS ONE 2013, 8:e74430.
160. Hara M., Kingsley C.I., Niimi M., Read S., Turvey S.E., Bushell A.R., Morris P.J., Powrie F., Wood K.J. IL-10 is required for regulatory T cells to mediate tolerance to alloantigens in vivo. J. Immunol. 2001, 166:3789-3796.
161. Nakamura K., Kitani A., Strober W. Cell contact-dependent immunosuppression by CD4(+)CD25(+) regulatory T cells is mediated by cell surface-bound transforming growth factor beta. J. Exp. Med. 2001, 194:629-644.
162. Sica A., Schioppa T., Mantovani A., Allavena P. Tumour-associated macrophages are a distinct M2 polarised population promoting tumour progression: potential targets of anti-cancer therapy. Eur. J. Cancer 2006, 42:717-727.
163. Biswas S.K., Mantovani A. Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nat. Immunol. 2010, 11:889-896.
164. Lee J.H., Lee G.T., Woo S.H., Ha Y.S., Kwon S.J., Kim W.J., Kim I.Y. BMP-6 in renal cell carcinoma promotes tumor proliferation through IL-10-dependent M2 polarization of tumor-associated macrophages. Cancer Res. 2013, 73:3604-3614.
165. Zhang Q.W., Liu L., Gong C.Y., Shi H.S., Zeng Y.H., Wang X.Z., Zhao Y.W., Wei Y.Q. Prognostic significance of tumor-associated macrophages in solid tumor: a meta-analysis of the literature. PLoS ONE 2012, 7:e50946.
166. Kawamura K., Komohara Y., Takaishi K., Katabuchi H., Takeya M. Detection of M2 macrophages and colony-stimulating factor 1 expression in serous and mucinous ovarian epithelial tumors. Pathol. Int. 2009, 59:300-305.
167. Komohara Y., Ohnishi K., Kuratsu J., Takeya M. Possible involvement of the M2 anti-inflammatory macrophage phenotype in growth of human gliomas. J. Pathol. 2008, 216:15-24.
168. van Dongen M., Savage N.D., Jordanova E.S., Briaire-de Bruijn I.H., Walburg K.V., Ottenhoff T.H., Hogendoorn P.C., van der Burg S.H., Gelderblom H., van Hall T. Anti-inflammatory M2 type macrophages characterize metastasized and tyrosine kinase inhibitor-treated gastrointestinal stromal tumors. Int. J. Cancer 2010, 127:899-909.
169. Tjiu J.W., Chen J.S., Shun C.T., Lin S.J., Liao Y.H., Chu C.Y., Tsai T.F., Chiu H.C., Dai Y.S., Inoue H., Yang P.C., Kuo M.L., Jee S.H. Tumor-associated macrophage-induced invasion and angiogenesis of human basal cell carcinoma cells by cyclooxygenase-2 induction. J. Invest. Dermatol. 2009, 129:1016-1025.
170. Kurahara H., Shinchi H., Mataki Y., Maemura K., Noma H., Kubo F., Sakoda M., Ueno S., Natsugoe S., Takao S. Significance of M2-polarized tumor-associated macrophage in pancreatic cancer. J. Surg. Res. 2011, 167:e211-e219.
171. Fend L., Accart N., Kintz J., Cochin S., Reymann C., Le Pogam F., Marchand J.B., Menguy T., Slos P., Rooke R., Fournel S., Bonnefoy J.Y., Préville X., Haegel H. Therapeutic effects of anti-CD115 monoclonal antibody in mouse cancer models through dual inhibition of tumor-associated macrophages and osteoclasts. PLoS ONE 2013, 8:e73310.
172. Ly L.V., Baghat A., Versluis M., Jordanova E.S., Luyten G.P., van Rooijen N., van Hall T., van der Velden P.A., Jager M.J. In aged mice, outgrowth of intraocular melanoma depends on proangiogenic M2-type macrophages. J. Immunol. 2010, 185:3481-3488.
173. Gazzaniga S., Bravo A.I., Guglielmotti A., van Rooijen N., Maschi F., Vecchi A., Mantovani A., Mordoh J., Wainstok R. Targeting tumor-associated macrophages and inhibition of MCP-1 reduce angiogenesis and tumor growth in a human melanoma xenograft. J. Invest. Dermatol. 2007, 127:2031-2041.
174. Zhang W., Zhu X.D., Sun H.C., Xiong Y.Q., Zhuang P.Y., Xu H.X., Kong L.Q., Wang L., Wu W.Z., Tang Z.Y. Depletion of tumor-associated macrophages enhances the effect of sorafenib in metastatic liver cancer models by antimetastatic and antiangiogenic effects. Clin. Cancer Res. 2010, 16:3420-3430.
175. Jahrsdörfer B., Vollmer A., Blackwell S.E., Maier J., Sontheimer K., Beyer T., Mandel B., Lunov O., Tron K., Nienhaus G.U., Simmet T., Debatin K.M., Weiner G.J., Fabricius D. Granzyme B produced by human plasmacytoid dendritic cells suppresses T-cell expansion. Blood 2010, 115:1156-1165.
176. Gilliet M., Liu Y.J. Generation of human CD8 T regulatory cells by CD40 ligand-activated plasmacytoid dendritic cells. J. Exp. Med. 2002, 195:695-704.
177. Ito T., Yang M., Wang Y.H., Lande R., Gregorio J., Perng O.A., Qin X.F., Liu Y.J., Gilliet M. Plasmacytoid dendritic cells prime IL-10-producing T regulatory cells by inducible costimulator ligand. J. Exp. Med. 2007, 204:105-115.
178. Faget J., Bendriss-Vermare N., Gobert M., Durand I., Olive D., Biota C., Bachelot T., Treilleux I., Goddard-Leon S., Lavergne E., Chabaud S., Blay J.Y., Caux C., Menetrier-Caux C. ICOS-ligand expression on plasmacytoid dendritic cells supports breast cancer progression by promoting the accumulation of immunosuppressive CD4+ T cells. Cancer Res. 2012, 72(23):6130-6141.
179. Sisirak V., Faget J., Gobert M., Goutagny N., Vey N., Treilleux I., Renaudineau S., Poyet G., Labidi-Galy S.I., Goddard-Leon S., Durand I., Le Mercier I., Bajard A., Bachelot T., Puisieux A., Puisieux I., Blay J.Y., Ménétrier-Caux C., Caux C., Bendriss-Vermare N. Impaired IFN-α production by plasmacytoid dendritic cells favors regulatory T-cell expansion that may contribute to breast cancer progression. Cancer Res. 2012, 72:5188-5197.
180. Jensen T.O., Schmidt H., Møller H.J., Donskov F., Høyer M., Sjoegren P., Christensen I.J., Steiniche T. Intratumoral neutrophils and plasmacytoid dendritic cells indicate poor prognosis and are associated with pSTAT3 expression in AJCC stage I/II melanoma. Cancer 2012, 118:2476-2485.
181. Zou W., Machelon V., Coulomb-L'Hermin A., Borvak J., Nome F., Isaeva T., Wei S., Krzysiek R., Durand-Gasselin I., Gordon A., Pustilnik T., Curiel D.T., Galanaud P., Capron F., Emilie D., Curiel T.J. Stromal-derived factor-1 in human tumors recruits and alters the function of plasmacytoid precursor dendritic cells. Nat. Med. 2001, 7:1339-1346.
182. Ostrand-Rosenberg S. Myeloid-derived suppressor cells: more mechanisms for inhibiting antitumor immunity. Cancer Immunol. Immunother. 2010, 59:1593-1600.
183. Rodriguez P.C., Quiceno D.G., Ochoa A.C. l-Arginine availability regulates T-lymphocyte cell-cycle progression. Blood 2007, 109:1568-1573.
184. Gabrilovich D.I., Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat. Rev. Immunol. 2009, 9:162-174.
185. Kohanbash G., McKaveney K., Sakaki M., Ueda R., Mintz A.H., Amankulor N., Fujita M., Ohlfest J.R., Okada H. GM-CSF promotes the immunosuppressive activity of glioma-infiltrating myeloid cells through interleukin-4 receptor-α. Cancer Res. 2013, 73:6413-6423.
186. Liu Y., Zeng B., Zhang Z., Zhang Y., Yang R. B7-H1 on myeloid-derived suppressor cells in immune suppression by a mouse model of ovarian cancer. Clin. Immunol. 2008, 129:471-481.
187. Arihara F., Mizukoshi E., Kitahara M., Takata Y., Arai K., Yamashita T., Nakamoto Y., Kaneko S. Increase in CD14+HLA-DR -/low myeloid-derived suppressor cells in hepatocellular carcinoma patients and its impact on prognosis. Cancer Immunol. Immunother. 2013, 62:1421-1430.
188. Zhang B., Wang Z., Wu L., Zhang M., Li W., Ding J., Zhu J., Wei H., Zhao K. Circulating and tumor-infiltrating myeloid-derived suppressor cells in patients with colorectal carcinoma. PLoS ONE 2013, 8:e57114.
189. Vuk-Pavlović S., Bulur P.A., Lin Y., Qin R., Szumlanski C.L., Zhao X., Dietz A.B. Immunosuppressive CD14+ HLA-DRlow/- monocytes in prostate cancer. Prostate 2010, 70:443-455.
190. Armand P., Nagler A., Weller E.A., Devine S.M., Avigan D.E., Chen Y.B., Kaminski M.S., Holland H.K., Winter J.N., Mason J.R., Fay J.W., Rizzieri D.A., Hosing C.M., Ball E.D., Uberti J.P., Lazarus H.M., Mapara M.Y., Gregory S.A., Timmerman J.M., Andorsky D., Or R., Waller E.K., Rotem-Yehudar R., Gordon L.I. Disabling immune tolerance by programmed Death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: results of an international phase II trial. J. Clin. Oncol. 2013, 31:4199-4206.
191. Hannesdóttir L., Tymoszuk P., Parajuli N., Wasmer M.H., Philipp S., Daschil N., Datta S., Koller J.B., Tripp C.H., Stoitzner P., Müller-Holzner E., Wiegers G.J., Sexl V., Villunger A., Doppler W. Lapatinib and doxorubicin enhance the Stat1-dependent antitumor immune response. Eur. J. Immunol. 2013, 43:2718-2729.
192. Kim M.J., Jang J.W., Oh B.S., Kwon J.H., Chung K.W., Jung H.S., Jekarl D.W., Lee S. Change in inflammatory cytokine profiles after transarterial chemotherapy in patients with hepatocellular carcinoma. Cytokine 2013, 64:516-522.
193. Xu Y., Sun J., Sheard M.A., Tran H.C., Wan Z., Liu W.Y., Asgharzadeh S., Sposto R., Wu H.W., Seeger R.C. Lenalidomide overcomes suppression of human natural killer cell anti-tumor functions by neuroblastoma microenvironment-associated IL-6 and TGFβ1. Cancer Immunol. Immunother. 2013, 62:1637-1648.
194. Ahmadi T., Chong E.A., Gordon A., Aqui N.A., Nasta S.D., Svoboda J., Mato A.R., Schuster S.J. Combined lenalidomide, low-dose dexamethasone, and rituximab achieves durable responses in rituximab-resistant indolent and mantle cell lymphomas. Cancer 2013, 120(2):222-228.
195. Creelan B.C., Antonia S., Bepler G., Garrett T.J., Simon G.R., Soliman H.H. Indoleamine 2,3-dioxygenase activity and clinical outcome following induction chemotherapy and concurrent chemoradiation in stage III non-small cell lung cancer. Oncoimmunology 2013, 2:e23428.
196. Wong J.L., Berk E., Edwards R.P., Kalinski P. IL-18-primed helper NK cells collaborate with dendritic cells to promote recruitment of effector CD8+ T cells to the tumor microenvironment. Cancer Res. 2013, 73:4653-4662.
197. Donini M., Marongiu L., Fontana E., Dusi S. Prostate carcinoma cells LNCaP and glucan cooperate in induction of cytokine synthesis by dendritic cells: effect on natural killer cells and CD4+ lymphocytes activation. Prostate 2012, 72:566-576.
198. Calcinotto A., Filipazzi P., Grioni M., Iero M., De Milito A., Ricupito A., Cova A., Canese R., Jachetti E., Rossetti M., Huber V., Parmiani G., Generoso L., Santinami M., Borghi M., Fais S., Bellone M., Rivoltini L. Modulation of microenvironment acidity reverses anergy in human and murine tumor-infiltrating T lymphocytes. Cancer Res. 2012, 72:2746-2756.
199. Bellone S., Roque D., Cocco E., Gasparrini S., Bortolomai I., Buza N., Abu-Khalaf M., Silasi D.A., Ratner E., Azodi M., Schwartz P.E., Rutherford T.J., Pecorelli S., Santin A.D. Downregulation of membrane complement inhibitors CD55 and CD59 by siRNA sensitises uterine serous carcinoma overexpressing Her2/neu to complement and antibody-dependent cell cytotoxicity in vitro: implications for trastuzumab-based immunotherapy. Br. J. Cancer 2012, 106:1543-1550.
200. Sarrabayrouse G., Pich C., Moriez R., Armand-Labit V., Rochaix P., Favre G., Tilkin-Mariamé A.F. Melanoma cells treated with GGTI and IFN-gamma allow murine vaccination and enhance cytotoxic response against human melanoma cells. PLoS ONE 2010, 5:e9043.
201. LaCasse C.J., Janikashvili N., Larmonier C.B., Alizadeh D., Hanke N., Kartchner J., Situ E., Centuori S., Har-Noy M., Bonnotte B., Katsanis E., Larmonier N. Th-1 lymphocytes induce dendritic cell tumor killing activity by an IFN-γ-dependent mechanism. J. Immunol. 2011, 187:6310-6317.
202. Stewart D.A., Yang Y., Makowski L., Troester M.A. Basal-like breast cancer cells induce phenotypic and genomic changes in macrophages. Mol. Cancer Res. 2012, 10:727-738.
203. Idoyaga J., Moreno J., Bonifaz L. Tumor cells prevent mouse dendritic cell maturation induced by TLR ligands. Cancer Immunol. Immunother. 2007, 56:1237-1250.
204. Kamoshida G., Matsuda A., Miura R., Takashima Y., Katsura A., Tsuji T. Potentiation of tumor cell invasion by co-culture with monocytes accompanying enhanced production of matrix metalloproteinase and fibronectin. Clin. Exp. Metastasis 2013, 30:289-297.
205. Bohrer L.R., Schwertfeger K.L. Macrophages promote fibroblast growth factor receptor-driven tumor cell migration and invasion in a CXCR2-dependent manner. Mol. Cancer Res. 2012, 10:1294-1305.
206. Winter H., van den Engel N.K., Rüttinger D., Schmidt J., Schiller M., Poehlein C.H., Löhe F., Fox B.A., Jauch K.W., Hatz R.A., Hu H.M. Therapeutic T cells induce tumor-directed chemotaxis of innate immune cells through tumor-specific secretion of chemokines and stimulation of B16BL6 melanoma to secrete chemokines. J. Transl. Med. 2007, 5:56.
207. Liu C.Z., Zhang L., Chang X.H., Cheng Y.X., Cheng H.Y., Ye X., Fu T.Y., Chen J., Cui H. Overexpression and immunosuppressive functions of transforming growth factor 1, vascular endothelial growth factor and interleukin-10 in epithelial ovarian cancer. Chin. J. Cancer Res. 2012, 24:130-137.
208. Li R., Rüttinger D., Si L.S., Wang Y.L. Analysis of the immunological microenvironment at the tumor site in patients with non-small cell lung cancer. Langenbecks Arch. Surg. 2003, 388:406-412.
209. Yamamura M., Modlin R.L., Ohmen J.D., Moy R.L. Local expression of antiinflammatory cytokines in cancer. J. Clin. Invest. 1993, 91:1005-1010.
210. Siegel P.M., Massagué J. Cytostatic and apoptotic actions of TGF-beta in homeostasis and cancer. Nat. Rev. Cancer 2003, 3:807-821.
211. Ikushima H., Miyazono K. TGFbeta signalling: a complex web in cancer progression. Nat. Rev. Cancer 2010, 10:415-424.
212. Santibanez J.F. Transforming growth factor-Beta and urokinase-type plasminogen activator: dangerous partners in tumorigenesis-implications in skin cancer. ISRN Dermatol. 2013, 2013:597927.
213. Adorno M., Cordenonsi M., Montagner M., Dupont S., Wong C., Hann B., Solari A., Bobisse S., Rondina M.B., Guzzardo V., Parenti A.R., Rosato A., Bicciato S., Balmain A., Piccolo S. A mutant-p53/Smad complex opposes p63 to empower TGFbeta-induced metastasis. Cell 2009, 137:87-98.
214. Liu I.M., Schilling S.H., Knouse K.A., Choy L., Derynck R., Wang X.F. TGFbeta-stimulated Smad1/5 phosphorylation requires the ALK5 L45 loop and mediates the pro-migratory TGFbeta switch. EMBO J. 2009, 28:88-98.
215. Stearns M.E., Garcia F.U., Fudge K., Rhim J., Wang M. Role of interleukin 10 and transforming growth factor beta1 in the angiogenesis and metastasis of human prostate primary tumor lines from orthotopic implants in severe combined immunodeficiency mice. Clin. Cancer Res. 1999, 5:711-720.
216. Giampieri S., Manning C., Hooper S., Jones L., Hill C.S., Sahai E. Localized and reversible TGFbeta signalling switches breast cancer cells from cohesive to single cell motility. Nat. Cell Biol. 2009, 11:1287-1296.
217. Verona E.V., Elkahloun A.G., Yang J., Bandyopadhyay A., Yeh I.T., Sun L.Z. Transforming growth factor-beta signaling in prostate stromal cells supports prostate carcinoma growth by up-regulating stromal genes related to tissue remodeling. Cancer Res. 2007, 67:5737-5746.
218. Alas S., Emmanouilides C., Bonavida B. Inhibition of interleukin 10 by rituximab results in down-regulation of bcl-2 and sensitization of B-cell non-Hodgkin's lymphoma to apoptosis. Clin. Cancer Res. 2001, 7:709-723.
219. Zeng L., O'Connor C., Zhang J., Kaplan A.M., Cohen D.A. IL-10 promotes resistance to apoptosis and metastatic potential in lung tumor cell lines. Cytokine 2010, 49:294-302.
220. Yang J., Liao X., Agarwal M.K., Barnes L., Auron P.E., Stark G.R. Unphosphorylated STAT3 accumulates in response to IL-6 and activates transcription by binding to NFkappaB. Genes Dev. 2007, 21:1396-1408.
221. Ara T., Song L., Shimada H., Keshelava N., Russell H.V., Metelitsa L.S., Groshen S.G., Seeger R.C., DeClerck Y.A. Interleukin-6 in the bone marrow microenvironment promotes the growth and survival of neuroblastoma cells. Cancer Res. 2009, 69:329-337.
222. Rebouissou S., Amessou M., Couchy G., Poussin K., Imbeaud S., Pilati C., Izard T., Balabaud C., Bioulac-Sage P., Zucman-Rossi J. Frequent in-frame somatic deletions activate gp130 in inflammatory hepatocellular tumours. Nature 2009, 457:200-204.
223. Grivennikov S., Karin E., Terzic J., Mucida D., Yu G.Y., Vallabhapurapu S., Scheller J., Rose-John S., Cheroutre H., Eckmann L., Karin M. IL-6 and STAT3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. Cancer Cell 2009, 15:103-113.
224. Numasaki M., Fukushi J., Ono M., Narula S.K., Zavodny P.J., Kudo T., Robbins P.D., Tahara H., Lotze M.T. Interleukin-17 promotes angiogenesis and tumor growth. Blood 2003, 101:2620-2627.
225. Wang L., Yi T., Kortylewski M., Pardoll D.M., Zeng D., Yu H. IL-17 can promote tumor growth through an IL-6-STAT3 signaling pathway. J. Exp. Med. 2009, 206:1457-1464.
226. Hirt C., Papadimitropoulos A., Mele V., Muraro M.G., Mengus C., Iezzi G., Terracciano L., Martin I., Spagnoli G.C. "In vitro" 3D models of tumor-immune system interaction. Adv. Drug Deliv. Rev. 2014, (in press). 10.1016/j.addr.2014.05.003.
227. Warburg O. On respiratory impairment in cancer cells. Science 1956, 124:269-270.
228. Gatenby R.A., Gillies R.J. Why do cancers have high aerobic glycolysis?. Nat. Rev. Cancer 2004, 4:891-899.
229. Hsu P.P., Sabatini D.M. Cancer cell metabolism: Warburg and beyond. Cell 2008, 134:703-707.
230. Vander Heiden M.G., Cantley L.C., Thompson C.B. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 2009, 324:1029-1033.
231. Kimura H., Braun R.D., Ong E.T., Hsu R., Secomb T.W., Papahadjopoulos D., Hong K., Dewhirst M.W. Fluctuations in red cell flux in tumor microvessels can lead to transient hypoxia and reoxygenation in tumor parenchyma. Cancer Res. 1996, 56:5522-5528.
232. Braun R.D., Lanzen J.L., Dewhirst M.W. Fourier analysis of fluctuations of oxygen tension and blood flow in R3230Ac tumors and muscle in rats. Am. J. Physiol. 1999, 277:H551-H568.
233. Altman B.J., Dang C.V. Normal and cancer cell metabolism: lymphocytes and lymphoma. FEBS J. 2012, 279:2598-2609.
234. Dang C.V. MYC, metabolism, cell growth, and tumorigenesis. Cold Spring Harb. Perspect. Med. 2013, 3.
235. Vander Heiden M.G. Targeting cancer metabolism: a therapeutic window opens. Nat. Rev. Drug Discov. 2011, 10:671-684.
236. Cairns R.A., Harris I.S., Mak T.W. Regulation of cancer cell metabolism. Nat. Rev. Cancer 2011, 11:85-95.
237. DeBerardinis R.J., Mancuso A., Daikhin E., Nissim I., Yudkoff M., Wehrli S., Thompson C.B. Beyond aerobic glycolysis: transformed cells can engage in glutamine metabolism that exceeds the requirement for protein and nucleotide synthesis. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:19345-19350.
238. Scott D.A., Richardson A.D., Filipp F.V., Knutzen C.A., Chiang G.G., Ronai Z.A., Osterman A.L., Smith J.W. Comparative metabolic flux profiling of melanoma cell lines: beyond the Warburg effect. J. Biol. Chem. 2011, 286:42626-42634.
239. Fuchs B.C., Bode B.P. Stressing out over survival: glutamine as an apoptotic modulator. J. Surg. Res. 2006, 131:26-40.
240. Son J., Lyssiotis C.A., Ying H., Wang X., Hua S., Ligorio M., Perera R.M., Ferrone C.R., Mullarky E., Shyh-Chang N., Kang Y., Fleming J.B., Bardeesy N., Asara J.M., Haigis M.C., DePinho R.A., Cantley L.C., Kimmelman A.C. Glutamine supports pancreatic cancer growth through a KRAS-regulated metabolic pathway. Nature 2013, 496:101-105.
241. Gatenby R.A., Gawlinski E.T., Gmitro A.F., Kaylor B., Gillies R.J. Acid-mediated tumor invasion: a multidisciplinary study. Cancer Res. 2006, 66:5216-5223.
242. Estrella V., Chen T., Lloyd M., Wojtkowiak J., Cornnell H.H., Ibrahim-Hashim A., Bailey K., Balagurunathan Y., Rothberg J.M., Sloane B.F., Johnson J., Gatenby R.A., Gillies R.J. Acidity generated by the tumor microenvironment drives local invasion. Cancer Res. 2013, 73:1524-1535.
243. Gallagher S.M., Castorino J.J., Philp N.J. Interaction of monocarboxylate transporter 4 with beta1-integrin and its role in cell migration. Am. J. Physiol. Cell Physiol. 2009, 296:C414-C421.
244. Izumi H., Takahashi M., Uramoto H., Nakayama Y., Oyama T., Wang K.Y., Sasaguri Y., Nishizawa S., Kohno K. Monocarboxylate transporters 1 and 4 are involved in the invasion activity of human lung cancer cells. Cancer Sci. 2011, 102:1007-1013.
245. Kato Y., Lambert C.A., Colige A.C., Mineur P., Noël A., Frankenne F., Foidart J.M., Baba M., Hata R., Miyazaki K., Tsukuda M. Acidic extracellular pH induces matrix metalloproteinase-9 expression in mouse metastatic melanoma cells through the phospholipase d-mitogen-activated protein kinase signaling. J. Biol. Chem. 2005, 280:10938-10944.
246. Rofstad E.K., Mathiesen B., Kindem K., Galappathi K. Acidic extracellular pH promotes experimental metastasis of human melanoma cells in athymic nude mice. Cancer Res. 2006, 66:6699-6707.
247. Rozhin J., Sameni M., Ziegler G., Sloane B.F. Pericellular pH affects distribution and secretion of cathepsin B in malignant cells. Cancer Res. 1994, 54:6517-6525.
248. Ruan G.X., Kazlauskas A. Lactate engages receptor tyrosine kinases Axl, Tie2, and vascular endothelial growth factor receptor 2 to activate phosphoinositide 3-kinase/Akt and promote angiogenesis. J. Biol. Chem. 2013, 288:21161-21172.
249. Polet F., Feron O. Endothelial cell metabolism and tumour angiogenesis: glucose and glutamine as essential fuels and lactate as the driving force. J. Intern. Med. 2013, 273:156-165.
250. Sonveaux P., Copetti T., De Saedeleer C.J., Végran F., Verrax J., Kennedy K.M., Moon E.J., Dhup S., Danhier P., Frérart F., Gallez B., Ribeiro A., Michiels C., Dewhirst M.W., Feron O. Targeting the lactate transporter MCT1 in endothelial cells inhibits lactate-induced HIF-1 activation and tumor angiogenesis. PLoS ONE 2012, 7:e33418.
251. Végran F., Boidot R., Michiels C., Sonveaux P., Feron O. Lactate influx through the endothelial cell monocarboxylate transporter MCT1 supports an NF-κB/IL-8 pathway that drives tumor angiogenesis. Cancer Res. 2011, 71:2550-2560.
252. Beckert S., Farrahi F., Aslam R.S., Scheuenstuhl H., Königsrainer A., Hussain M.Z., Hunt T.K. Lactate stimulates endothelial cell migration. Wound Repair Regen. 2006, 14:321-324.
253. Wojtkowiak J.W., Verduzco D., Schramm K.J., Gillies R.J. Drug resistance and cellular adaptation to tumor acidic pH microenvironment. Mol. Pharm. 2011, 8:2032-2038.
254. Adams D.J., Morgan L.R. Tumor physiology and charge dynamics of anticancer drugs: implications for camptothecin-based drug development. Curr. Med. Chem. 2011, 18:1367-1372.
255. Vukovic V., Tannock I.F. Influence of low pH on cytotoxicity of paclitaxel, mitoxantrone and topotecan. Br. J. Cancer 1997, 75:1167-1172.
256. Raghunand N., He X., van Sluis R., Mahoney B., Baggett B., Taylor C.W., Paine-Murrieta G., Roe D., Bhujwalla Z.M., Gillies R.J. Enhancement of chemotherapy by manipulation of tumour pH. Br. J. Cancer 1999, 80:1005-1011.
257. Lotz C., Kelleher D.K., Gassner B., Gekle M., Vaupel P., Thews O. Role of the tumor microenvironment in the activity and expression of the p-glycoprotein in human colon carcinoma cells. Oncol. Rep. 2007, 17:239-244.
258. Frézard F., Pereira-Maia E., Quidu P., Priebe W., Garnier-Suillerot A. P-glycoprotein preferentially effluxes anthracyclines containing free basic versus charged amine. Eur. J. Biochem. 2001, 268:1561-1567.
259. Gerweck L.E., Vijayappa S., Kozin S. Tumor pH controls the in vivo efficacy of weak acid and base chemotherapeutics. Mol. Cancer Ther. 2006, 5:1275-1279.
260. Skarsgard L.D., Skwarchuk M.W., Vinczan A., Kristl J., Chaplin D.J. The cytotoxicity of melphalan and its relationship to pH, hypoxia and drug uptake. Anticancer Res. 1995, 15:219-223.
261. Du J.Z., Mao C.Q., Yuan Y.Y., Yang X.Z., Wang J. Tumor extracellular acidity-activated nanoparticles as drug delivery systems for enhanced cancer therapy. Biotechnol. Adv. 2013, 32(4):789-803.
262. Lardner A. The effects of extracellular pH on immune function. J. Leukoc. Biol. 2001, 69:522-530.
263. Mendler A.N., Hu B., Prinz P.U., Kreutz M., Gottfried E., Noessner E. Tumor lactic acidosis suppresses CTL function by inhibition of p38 and JNK/c-Jun activation. Int. J. Cancer 2012, 131:633-640.
264. Ohashi T., Akazawa T., Aoki M., Kuze B., Mizuta K., Ito Y., Inoue N. Dichloroacetate improves immune dysfunction caused by tumor-secreted lactic acid and increases antitumor immunoreactivity. Int. J. Cancer 2013, 133(5):1107-1118.
265. Fischer K., Hoffmann P., Voelkl S., Meidenbauer N., Ammer J., Edinger M., Gottfried E., Schwarz S., Rothe G., Hoves S., Renner K., Timischl B., Mackensen A., Kunz-Schughart L., Andreesen R., Krause S.W., Kreutz M. Inhibitory effect of tumor cell-derived lactic acid on human T cells. Blood 2007, 109:3812-3819.
266. Gottfried E., Kunz-Schughart L.A., Ebner S., Mueller-Klieser W., Hoves S., Andreesen R., Mackensen A., Kreutz M. Tumor-derived lactic acid modulates dendritic cell activation and antigen expression. Blood 2006, 107:2013-2021.
267. Choi S.Y., Collins C.C., Gout P.W., Wang Y. Cancer-generated lactic acid: a regulatory, immunosuppressive metabolite?. J. Pathol. 2013, 230:350-355.
268. Goetze K., Walenta S., Ksiazkiewicz M., Kunz-Schughart L.A., Mueller-Klieser W. Lactate enhances motility of tumor cells and inhibits monocyte migration and cytokine release. Int. J. Oncol. 2011, 39:453-463.
269. 2+ complex to breast and colon cancer cells. Chemotherapy 2013, 59:112-120.
270. Tavares-Valente D., Baltazar F., Moreira R., Queirós O. Cancer cell bioenergetics and pH regulation influence breast cancer cell resistance to paclitaxel and doxorubicin. J. Bioenerg. Biomembr. 2013, 45:467-475.
271. Mazzio E.A., Boukli N., Rivera N., Soliman K.F. Pericellular pH homeostasis is a primary function of the Warburg effect: inversion of metabolic systems to control lactate steady state in tumor cells. Cancer Sci. 2012, 103:422-432.
272. Marino M.L., Pellegrini P., Di Lernia G., Djavaheri-Mergny M., Brnjic S., Zhang X., Hägg M., Linder S., Fais S., Codogno P., De Milito A. Autophagy is a protective mechanism for human melanoma cells under acidic stress. J. Biol. Chem. 2012, 287:30664-30676.
273. Park H.J., Lee S.H., Chung H., Rhee Y.H., Lim B.U., Ha S.W., Griffin R.J., Lee H.S., Song C.W., Choi E.K. Influence of environmental pH on G2-phase arrest caused by ionizing radiation. Radiat. Res. 2003, 159:86-93.
274. Ohtsubo T., Igawa H., Saito T., Matsumoto H., Park H.J., Song C.W., Kano E., Saito H. Acidic environment modifies heat- or radiation-induced apoptosis in human maxillary cancer cells. Int. J. Radiat. Oncol. Biol. Phys. 2001, 49:1391-1398.
275. McBrian M.A., Behbahan I.S., Ferrari R., Su T., Huang T.W., Li K., Hong C.S., Christofk H.R., Vogelauer M., Seligson D.B., Kurdistani S.K. Histone acetylation regulates intracellular pH. Mol. Cell 2013, 49:310-321.
276. Shultz L.D., Lyons B.L., Burzenski L.M., Gott B., Chen X., Chaleff S., Kotb M., Gillies S.D., King M., Mangada J., Greiner D.L., Handgretinger R. Human lymphoid and myeloid cell development in NOD/LtSz-scid IL2R gamma null mice engrafted with mobilized human hemopoietic stem cells. J. Immunol. 2005, 174:6477-6489.
277. Rongvaux A., Willinger T., Martinek J., Strowig T., Gearty S.V., Teichmann L.L., Saito Y., Marches F., Halene S., Palucka A.K., Manz M.G., Flavell R.A. Development and function of human innate immune cells in a humanized mouse model. Nat. Biotechnol. 2014, 32:364-372.
278. Gilkes D.M., Semenza G.L., Wirtz D. Hypoxia and the extracellular matrix: drivers of tumour metastasis. Nat. Rev. Cancer 2014, 14:430-439.
279. Burkholder B., Huang R.Y., Burgess R., Luo S., Jones V.S., Zhang W., Lv Z.Q., Gao C.Y., Wang B.L., Zhang Y.M., Huang R.P. Tumor-induced perturbations of cytokines and immune cell networks. Biochim. Biophys. Acta 2014, 1845:182-201.
280. Zou W. Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat. Rev. Cancer 2005, 5:263-274.
281. Pardoll D.M. The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer 2012, 12:252-264.
282. Motz G.T., Coukos G. Deciphering and reversing tumor immune suppression. Immunity 2013, 39:61-73.
283. Parks S.K., Chiche J., Pouysségur J. Disrupting proton dynamics and energy metabolism for cancer therapy. Nat. Rev. Cancer 2013, 13:611-623.
284. Hirschhaeuser F., Sattler U.G., Mueller-Klieser W. Lactate: a metabolic key player in cancer. Cancer Res. 2011, 71:6921-6925.
285. Casazza A., Di Conza G., Wenes M., Finisguerra V., Deschoemaeker S., Mazzone M. Tumor stroma: a complexity dictated by the hypoxic tumor microenvironment. Oncogene 2014, 33:1743-1754.
286. Masson N., Ratcliffe P.J. Hypoxia signaling pathways in cancer metabolism: the importance of co-selecting interconnected physiological pathways. Cancer Metab. 2014, 2:3.
287. Wouters B.G., Koritzinsky M. Hypoxia signalling through mTOR and the unfolded protein response in cancer. Nat. Rev. Cancer 2008, 8:851-864.
288. Amaravadi R.K., Thompson C.B. The roles of therapy-induced autophagy and necrosis in cancer treatment. Clin. Cancer Res. 2007, 13:7271-7279.
289. Jain M.V., Paczulla A.M., Klonisch T., Dimgba F.N., Rao S.B., Roberg K., Schweizer F., Lengerke C., Davoodpour P., Palicharla V.R., Maddika S., Łos M. Interconnections between apoptotic, autophagic and necrotic pathways: implications for cancer therapy development. J. Cell. Mol. Med. 2013, 17:12-29.
290. Vanden Berghe T., Linkermann A., Jouan-Lanhouet S., Walczak H., Vandenabeele P. Regulated necrosis: the expanding network of non-apoptotic cell death pathways. Nat. Rev. Mol. Cell Biol. 2014, 15:135-147.
291. Kaczmarek A., Vandenabeele P., Krysko D.V. Necroptosis: the release of damage-associated molecular patterns and its physiological relevance. Immunity 2013, 38:209-223.
292. Appay V., Douek D.C., Price D.A. CD8+ T cell efficacy in vaccination and disease. Nat. Med. 2008, 14:623-628.
293. + T cells. Nat. Rev. Immunol. 2011, 11:645-657.
294. Cullen S.P., Brunet M., Martin S.J. Granzymes in cancer and immunity. Cell Death Differ. 2010, 17:616-623.
295. Maher J., Davies E.T. Targeting cytotoxic T lymphocytes for cancer immunotherapy. Br. J. Cancer 2004, 91:817-821.
296. Robbins P.F., Lu Y.C., El-Gamil M., Li Y.F., Gross C., Gartner J., Lin J.C., Teer J.K., Cliften P., Tycksen E., Samuels Y., Rosenberg S.A. Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells. Nat. Med. 2013, 19:747-752.
297. Marcus A., Gowen B.G., Thompson T.W., Iannello A., Ardolino M., Deng W., Wang L., Shifrin N., Raulet D.H. Recognition of tumors by the innate immune system and natural killer cells. Adv. Immunol. 2014, 122:91-128.
298. Raulet D.H., Guerra N. Oncogenic stress sensed by the immune system: role of natural killer cell receptors. Nat. Rev. Immunol. 2009, 9:568-580.
299. Kennedy R., Celis E. Multiple roles for CD4+ T cells in anti-tumor immune responses. Immunol. Rev. 2008, 222:129-144.
300. Knutson K.L., Disis M.L. Tumor antigen-specific T helper cells in cancer immunity and immunotherapy. Cancer Immunol. Immunother. 2005, 54:721-728.
301. Cerundolo V., Silk J.D., Masri S.H., Salio M. Harnessing invariant NKT cells in vaccination strategies. Nat. Rev. Immunol. 2009, 9:28-38.
302. Terabe M., Berzofsky J.A. The role of NKT cells in tumor immunity. Adv. Cancer Res. 2008, 101:277-348.
303. Gabrilovich D.I., Ostrand-Rosenberg S., Bronte V. Coordinated regulation of myeloid cells by tumours. Nat. Rev. Immunol. 2012, 12:253-268.
304. Murray P.J., Wynn T.A. Protective and pathogenic functions of macrophage subsets. Nat. Rev. Immunol. 2011, 11:723-737.
305. Muranski P., Restifo N.P. Essentials of Th17 cell commitment and plasticity. Blood 2013, 121:2402-2414.
306. Zou W., Restifo N.P. T(H)17 cells in tumour immunity and immunotherapy. Nat. Rev. Immunol. 2010, 10:248-256.
307. Ye J., Livergood R.S., Peng G. The role and regulation of human Th17 cells in tumor immunity. Am. J. Pathol. 2013, 182:10-20.
308. Hemdan N.Y. Anti-cancer versus cancer-promoting effects of the interleukin-17-producing T helper cells. Immunol. Lett. 2013, 149:123-133.
309. Onishi Y., Fehervari Z., Yamaguchi T., Sakaguchi S. Foxp3+ natural regulatory T cells preferentially form aggregates on dendritic cells in vitro and actively inhibit their maturation. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:10113-10118.
310. Grossman W.J., Verbsky J.W., Barchet W., Colonna M., Atkinson J.P., Ley T.J. Human T regulatory cells can use the perforin pathway to cause autologous target cell death. Immunity 2004, 21:589-601.
311. Gondek D.C., Lu L.F., Quezada S.A., Sakaguchi S., Noelle R.J. Cutting edge: contact-mediated suppression by CD4+ CD25+ regulatory cells involves a granzyme B-dependent, perforin-independent mechanism. J. Immunol. 2005, 174:1783-1786.
312. Lewis C.E., Leek R., Harris A., McGee J.O. Cytokine regulation of angiogenesis in breast cancer: the role of tumor-associated macrophages. J. Leukoc. Biol. 1995, 57:747-751.
313. Schoppmann S.F., Birner P., Stöckl J., Kalt R., Ullrich R., Caucig C., Kriehuber E., Nagy K., Alitalo K., Kerjaschki D. Tumor-associated macrophages express lymphatic endothelial growth factors and are related to peritumoral lymphangiogenesis. Am. J. Pathol. 2002, 161:947-956.
314. Giraudo E., Inoue M., Hanahan D. An amino-bisphosphonate targets MMP-9-expressing macrophages and angiogenesis to impair cervical carcinogenesis. J. Clin. Invest. 2004, 114:623-633.
315. Solinas G., Schiarea S., Liguori M., Fabbri M., Pesce S., Zammataro L., Pasqualini F., Nebuloni M., Chiabrando C., Mantovani A., Allavena P. Tumor-conditioned macrophages secrete migration-stimulating factor: a new marker for M2-polarization, influencing tumor cell motility. J. Immunol. 2010, 185:642-652.
316. Wyckoff J., Wang W., Lin E.Y., Wang Y., Pixley F., Stanley E.R., Graf T., Pollard J.W., Segall J., Condeelis J. A paracrine loop between tumor cells and macrophages is required for tumor cell migration in mammary tumors. Cancer Res. 2004, 64:7022-7029.
317. Conrad C., Gregorio J., Wang Y.H., Ito T., Meller S., Hanabuchi S., Anderson S., Atkinson N., Ramirez P.T., Liu Y.J., Freedman R., Gilliet M. Plasmacytoid dendritic cells promote immunosuppression in ovarian cancer via ICOS costimulation of Foxp3(+) T-regulatory cells. Cancer Res. 2012, 72:5240-5249.
318. Rodriguez P.C., Quiceno D.G., Zabaleta J., Ortiz B., Zea A.H., Piazuelo M.B., Delgado A., Correa P., Brayer J., Sotomayor E.M., Antonia S., Ochoa J.B., Ochoa A.C. Arginase I production in the tumor microenvironment by mature myeloid cells inhibits T-cell receptor expression and antigen-specific T-cell responses. Cancer Res. 2004, 64:5839-5849.
319. Srivastava M.K., Sinha P., Clements V.K., Rodriguez P., Ostrand-Rosenberg S. Myeloid-derived suppressor cells inhibit T-cell activation by depleting cystine and cysteine. Cancer Res. 2010, 70:68-77.
320. Nagaraj S., Gupta K., Pisarev V., Kinarsky L., Sherman S., Kang L., Herber D.L., Schneck J., Gabrilovich D.I. Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer. Nat. Med. 2007, 13:828-835.
321. Hanson E.M., Clements V.K., Sinha P., Ilkovitch D., Ostrand-Rosenberg S. Myeloid-derived suppressor cells down-regulate l-selectin expression on CD4+ and CD8+ T cells. J. Immunol. 2009, 183:937-944.
322. DeNardo D.G., Andreu P., Coussens L.M. Interactions between lymphocytes and myeloid cells regulate pro- versus anti-tumor immunity. Cancer Metastasis Rev. 2010, 29:309-316.
323. Grivennikov S.I., Greten F.R., Karin M. Immunity, inflammation, and cancer. Cell 2010, 140:883-899.